Inflammation and Huntington’s disease – a neglected therapeutic target?

References

• Tabrizi SJ, Flower MD, Ross CA, et al. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities. Nat Rev Neurol. 2020;16(10):529–546. Available from: https://www.nature.com/articles/s41582-020-0389-4.
   PubMed Web of Science ®Google Scholar
• Migliore S, Jankovic J, Squitieri F Genetic counseling in Huntington’s disease: potential new challenges on horizon? Front Neurol. 2019;10:453.
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Schobel S, Gantman EC, et al. A biological classification of Huntington’s disease: the integrated staging system. Lancet Neurol. 2022;21(7):632–644. Available from: http://www.thelancet.com/article/S147444222200120X/fulltext.
   PubMed Web of Science ®Google Scholar
• Li S, Li XJ Multiple pathways contribute to the pathogenesis of Huntington disease. Mol Neurodegener. 2006;1(1):1–10. Available from: https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-1-19
   Google Scholar
• Scahill RI, Zeun P, Osborne-Crowley K, et al. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington’s disease Young Adult Study (HD-YAS): a cross-sectional analysis. Lancet Neurol. 2020;19(6):502–512. Available from: http://www.thelancet.com/article/S1474442220301435/fulltext.
   PubMed Web of Science ®Google Scholar
• Li Q, Barres BA Microglia and macrophages in brain homeostasis and disease. Nat Rev Immunol. 2017;18(4):225–242.
   PubMed Web of Science ®Google Scholar
• Frost JL, Schafer DP Microglia: architects of the developing nervous system. Trends Cell Biol. 2016;26(8):587. Available from: /pmc/articles/PMC4961529/
   PubMed Web of Science ®Google Scholar
• Colonna M, Butovsky O Microglia function in the central nervous system during health and neurodegeneration. Annu Rev Immunol. 2017;35(1):441. Available from: /pmc/articles/PMC8167938/
   PubMed Web of Science ®Google Scholar
• Jurga AM, Paleczna M, Kuter KZ Overview of general and discriminating markers of differential microglia phenotypes. Front Cell Neurosci. 2020;14:544457.
   Web of Science ®Google Scholar
• Ransohoff RM A polarizing question: do M1 and M2 microglia exist? Nat Neurosci. 2016;19(8):987–991. Available from: https://www.nature.com/articles/nn.4338
   PubMed Web of Science ®Google Scholar
• Paolicelli RC, Sierra A, Stevens B, et al. Microglia states and nomenclature: a field at its crossroads. Neuron. 2022;110(21):3458. Available from: /pmc/articles/PMC9999291/.
   PubMed Web of Science ®Google Scholar
• Crotti A, Benner C, Kerman BE, et al. Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat Neurosci. 2014;17(4):513. Available from: /pmc/articles/PMC4113004/
   PubMed Web of Science ®Google Scholar
• Stöberl N, Donaldson J, Binda CS, et al. Mutant huntingtin confers cell-autonomous phenotypes on Huntington’s disease iPSC-derived microglia. Sci Rep. 2023;13(1):1–15. Available from: https://www.nature.com/articles/s41598-023-46852-z
   PubMed Web of Science ®Google Scholar
• Paldino E, D’Angelo V, Sancesario G, et al. Pyroptotic cell death in the R6/2 mouse model of Huntington’s disease: new insight on the inflammasome. Cell Death Discov. 2020;6:6. Available from: https://pubmed.ncbi.nlm.nih.gov/32821438/
   PubMed Web of Science ®Google Scholar
• Simmons DA, Casale M, Alcon B, et al. Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington’s disease. Glia. 2007;55(10):1074–1084. Available from: https://pubmed.ncbi.nlm.nih.gov/17551926/
   PubMed Web of Science ®Google Scholar
• Palazuelos J, Aguado T, Pazos MR, et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington’s disease excitotoxicity. Brain. 2009;132(11):3152–3164.
   PubMedGoogle Scholar
• Godavarthi SK, Narender D, Mishra A, et al. Induction of chemokines, MCP-1, and KC in the mutant huntingtin expressing neuronal cells because of proteasomal dysfunction. J Neurochem. 2009;108(3):787–795. Available from: https://pubmed.ncbi.nlm.nih.gov/19187096/
   PubMed Web of Science ®Google Scholar
• Savage JC, St-Pierre MK, Carrier M, et al. Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington’s disease pathology. J Neuroinflammation. 2020;17(1):1–18. Available from: https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-020-01782-9
   PubMed Web of Science ®Google Scholar
• Franciosi S, Ryu JK, Shim Y, et al. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiol Dis. 2012;45(1):438–449. Available from: https://pubmed.ncbi.nlm.nih.gov/21946335/
   PubMed Web of Science ®Google Scholar
• Siew JJ, Chen HM, Chen HY, et al. Galectin-3 is required for the microglia-mediated brain inflammation in a model of Huntington’s disease. Nat Commun. 2019;10(1):1–18. Available from: https://www.nature.com/articles/s41467-019-11441-0
   PubMedGoogle Scholar
• Steinberg N, Galleguillos D, Zaidi A, et al. Naïve Huntington’s disease microglia mount a normal response to inflammatory stimuli but display a partially impaired development of innate immune tolerance that can be counteracted by ganglioside GM1. J Neuroinflammation. 2023;20(1):1–20. Available from: https://jneuroinflammation.biomedcentral.com/articles/10.1186/s12974-023-02963-y
   PubMed Web of Science ®Google Scholar
• Petkau TL, Hill A, Connolly C, et al. Mutant huntingtin expression in microglia is neither required nor sufficient to cause the Huntington’s disease-like phenotype in BACHD mice. Hum Mol Genet. 2019;28(10):1661–1670.
   PubMed Web of Science ®Google Scholar
• Vonsattel J-P, Myers RH, Stevens TJ, et al. Neuropathological Classification of Huntingtonʼs Disease. J Neuropathol Exp Neurol. 1985;44(6):559–577.
   PubMed Web of Science ®Google Scholar
• Sapp E, Kegel KB, Aronin N, et al. Early and progressive accumulation of reactive Microglia in the Huntington disease brain. J Neuropathol Exp Neurol. 2001;60(2):161–172.
   PubMed Web of Science ®Google Scholar
• Dowie MJ, Grimsey NL, Hoffman T, et al. Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington’s disease brain. J Chem Neuroanat. 2014;59–60:62–71.
   PubMed Web of Science ®Google Scholar
• Palpagama T, Mills AR, Ferguson MW, et al. Microglial and astrocytic responses in the Human Midcingulate cortex in Huntington’s disease. Ann Neurol. 2023;94(5):895–910. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/ana.26753
   PubMed Web of Science ®Google Scholar
• Singhrao SK, Neal JW, Morgan BP, et al. Increased complement biosynthesis by microglia and complement activation on neurons in huntington’s disease. Exp Neurol. 1999;159(2):362–376. doi: 10.1006/exnr.1999.7170.
   PubMed Web of Science ®Google Scholar
• Wilton DK, Mastro K, Heller MD, et al. Microglia and complement mediate early corticostriatal synapse loss and cognitive dysfunction in Huntington’s disease. Nat Med. 2023.
   Web of Science ®Google Scholar
• Maxan A, Mason S, Saint-Pierre M, et al. Outcome of cell suspension allografts in a patient with Huntington’s disease. Ann Neurol. 2018;84(6):950. Available from: /pmc/articles/PMC6587549/
   PubMed Web of Science ®Google Scholar
• Lavisse S, Guillermier M, Hérard AS, et al. Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. J Neurosci. 2012;32(32):10809–10818. Available from: https://www.jneurosci.org/content/32/32/10809
   PubMed Web of Science ®Google Scholar
• Pavese N, Gerhard A, Tai YF, et al. Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology. 2006;66(11):1638–1643. Available from: https://pubmed.ncbi.nlm.nih.gov/16769933/
   PubMed Web of Science ®Google Scholar
• Tai YF, Pavese N, Gerhard A, et al. Imaging microglial activation in Huntington’s disease. Brain Res Bull. 2007;72(2–3):148–151. Available from: https://pubmed.ncbi.nlm.nih.gov/17352938/
   PubMed Web of Science ®Google Scholar
• Politis M, Pavese N, Tai YF, et al. Hypothalamic involvement in Huntington’s disease: an in vivo PET study. Brain. 2008;131(11):2860–2869.
   PubMedGoogle Scholar
• Politis M, Pavese N, Tai YF, et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington’s disease: a multimodal imaging study. Hum Brain Mapp. 2011;32(2):258–270. Available from: https://pubmed.ncbi.nlm.nih.gov/21229614/
   PubMed Web of Science ®Google Scholar
• Politis M, Lahiri N, Niccolini F, et al. Increased central microglial activation associated with peripheral cytokine levels in premanifest Huntington’s disease gene carriers. Neurobiol Dis. 2015;83:115–121. Available from: https://pubmed.ncbi.nlm.nih.gov/26297319/
   PubMed Web of Science ®Google Scholar
• Lois C, González I, Izquierdo-García D, et al. Neuroinflammation in Huntington’s Disease: new Insights with 11 C-PBR28 PET/MRI. ACS Chem Neurosci. 2018;9(11):2563–2571. Available from: https://pubmed.ncbi.nlm.nih.gov/29719953/
   PubMed Web of Science ®Google Scholar
• Roussakis AA, Gennaro M, Gordon MF, et al. A PET-CT study on neuroinflammation in Huntington’s disease patients participating in a randomized trial with laquinimod. Brain Commun. 2023 5;5(2). doi: 10.1093/braincomms/fcad084
   PubMedGoogle Scholar
• Rocha NP, Charron O, Latham LB, et al. Microglia activation in basal ganglia is a late event in huntington disease pathophysiology. Neurol Neuroimmunol Neuroinflamm. 2021 8;8(3). Available from: https://pubmed.ncbi.nlm.nih.gov/33795375/
   PubMed Web of Science ®Google Scholar
• Simmons DA, James ML, Belichenko NP, et al. TSPO–PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington’s disease: preclinical evidence with the p75NTR ligand LM11A-31. Hum Mol Genet. 2018;27(16):2893. Available from: /pmc/articles/PMC6077813/
   PubMed Web of Science ®Google Scholar
• Simmons DA, Belichenko NP, Ford EC, et al. A small molecule p75NTR ligand normalizes signalling and reduces Huntington’s disease phenotypes in R6/2 and BACHD mice. Hum Mol Genet. 2016;25(22):4920. Available from: /pmc/articles/PMC5418739/
   PubMed Web of Science ®Google Scholar
• Simmons DA, Mills BD, Butler RR, et al. Neuroimaging, urinary, and plasma biomarkers of treatment response in huntington’s disease: preclinical evidence with the p75NTR Ligand LM11A-31. Neurotherapeutics. 2021;18(2):1039–1063. Available from: https://pubmed.ncbi.nlm.nih.gov/33786806/
   PubMed Web of Science ®Google Scholar
• Meyer JH, Cervenka S, Kim MJ, et al. Neuroinflammation in psychiatric disorders: PET imaging and promising new targets. Lancet Psychiatry. 2020;7(12):1064. Available from: /pmc/articles/PMC7893630/
   PubMed Web of Science ®Google Scholar
• Kreisl WC, Kim MJ, Coughlin JM, et al. PET imaging of neuroinflammation in neurological disorders. Lancet Neurol. 2020;19(11):940. Available from: /pmc/articles/PMC7912433/
   PubMed Web of Science ®Google Scholar
• Garrido-Mesa N, Zarzuelo A, Gálvez J Minocycline: far beyond an antibiotic. Br J Pharmacol. 2013;169(2):337. Available from: /pmc/articles/PMC3651660/
   PubMed Web of Science ®Google Scholar
• Chen M, Ona VO, Li M, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med. 2000;6(7):797–801. Available from: https://pubmed.ncbi.nlm.nih.gov/10888929/
   PubMed Web of Science ®Google Scholar
• Wang X, Zhu S, Drozda M, et al. Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington’s disease. Proc Natl Acad Sci U S A. 2003;100(18):10483–10487. Available from: https://pubmed.ncbi.nlm.nih.gov/12930891/
   PubMed Web of Science ®Google Scholar
• Blecharz-Lang KG, Patsouris V, Nieminen-Kelhä M, et al. Minocycline attenuates microglia/macrophage phagocytic activity and inhibits SAH-induced neuronal cell death and inflammation. Neurocrit Care. 2022;37(2):410. Available from: /pmc/articles/PMC9519684/
   PubMed Web of Science ®Google Scholar
• Stack EC, Smith KM, Ryu H, et al. Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington’s disease mice. Biochim Biophys Acta. 2006;1762(3):373–380. Available from: https://pubmed.ncbi.nlm.nih.gov/16364609/
   PubMed Web of Science ®Google Scholar
• Diguet E, Rouland R, Tison F Minocycline is not beneficial in a phenotypic mouse model of Huntington’s disease. Ann Neurol. 2003;54(6):841–842. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/ana.10818
   PubMed Web of Science ®Google Scholar
• Diguet E, Fernagut PO, Wei X, et al. Deleterious effects of minocycline in animal models of Parkinson’s disease and Huntington’s disease. Eur J Neurosci. 2004;19(12):3266–3276. Available from: https://pubmed.ncbi.nlm.nih.gov/15217383/
   PubMed Web of Science ®Google Scholar
• Smith DL, Woodman B, Mahal A, et al. Minocycline and doxycycline are not beneficial in a model of Huntington’s disease. Ann Neurol. 2003;54(2):186–196. Available from: https://pubmed.ncbi.nlm.nih.gov/12891671/
   PubMed Web of Science ®Google Scholar
• Thsgd I A futility study of minocycline in huntington’s disease. Mov Disord. 2010;25(13):2219. Available from: /pmc/articles/PMC8801051/
   PubMed Web of Science ®Google Scholar
• Shi Y, Mader M Brain penetrant kinase inhibitors: learning from kinase neuroscience discovery. Bioorg Med Chem Lett. 2018;28(11):1981–1991.
   PubMed Web of Science ®Google Scholar
• Madkour MM, Anbar HS, El-Gamal MI Current status and future prospects of p38α/MAPK14 kinase and its inhibitors. Eur J Med Chem. 2021;213:113216.
   PubMed Web of Science ®Google Scholar
• Alam JJ Selective brain-targeted antagonism of p38 MAPKα reduces hippocampal IL-1β levels and improves Morris water maze performance in aged rats. J Alzheimers Dis. 2015;48(1):219. Available from: /pmc/articles/PMC4923728/
   PubMed Web of Science ®Google Scholar
• Freeman MR Specification and morphogenesis of astrocytes. Science. 2010;330(6005):774–778. Available from: https://pubmed.ncbi.nlm.nih.gov/21051628/
   PubMed Web of Science ®Google Scholar
• Lee HG, Wheeler MA, Quintana FJ Function and therapeutic value of astrocytes in neurological diseases. Nat Rev Drug Discov. 2022;21(5):339–358. Available from: https://www.nature.com/articles/s41573-022-00390-x
   PubMed Web of Science ®Google Scholar
• Brown TG, Thayer MN, VanTreeck JG, et al. Striatal spatial heterogeneity, clustering, and white matter association of GFAP+ astrocytes in a mouse model of Huntington’s disease. Front Cell Neurosci. 2023;17:1094503. Available from: /pmc/articles/PMC10175581/
   PubMed Web of Science ®Google Scholar
• Faideau M, Kim J, Cormier K, et al. In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington’s disease subjects. Hum Mol Genet. 2010;19(15):3053–3067. Available from: https://pubmed.ncbi.nlm.nih.gov/20494921/
   PubMed Web of Science ®Google Scholar
• Benraiss A, Mariani JN, Osipovitch M, et al. Cell-intrinsic glial pathology is conserved across human and murine models of Huntington’s disease. Cell Rep. 2021;36(1):109308. Available from: https://pubmed.ncbi.nlm.nih.gov/34233199/
   PubMed Web of Science ®Google Scholar
• Hsiao HY, Chen YC, Chen HM, et al. A critical role of astrocyte-mediated nuclear factor-κB-dependent inflammation in Huntington’s disease. Hum Mol Genet. 2013;22(9):1826–1842. Available from: https://pubmed.ncbi.nlm.nih.gov/23372043/
   PubMed Web of Science ®Google Scholar
• Bradford J, Shin JY, Roberts M, et al. Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci U S A. 2009;106(52):22480. Available from: /pmc/articles/PMC2799722/
   PubMed Web of Science ®Google Scholar
• Wood TE, Barry J, Yang Z, et al. Mutant huntingtin reduction in astrocytes slows disease progression in the BACHD conditional Huntington’s disease mouse model. Hum Mol Genet. 2019;28(3):487–500. Available from: https://pubmed.ncbi.nlm.nih.gov/30312396/
   PubMed Web of Science ®Google Scholar
• Benraiss A, Wang S, Herrlinger S, et al. Human glia can both induce and rescue aspects of disease phenotype in Huntington disease. Nat Commun. 2016;7(1). doi: 10.1038/ncomms11758.
   PubMedGoogle Scholar
• Myers RH, Vonsattel JP, Paskevich PA, et al. Decreased neuronal and increased oligodendroglial densities in Huntington’s disease caudate nucleus. J Neuropathol Exp Neurol. 1991;50(6):729–742.
   PubMed Web of Science ®Google Scholar
• Al-Dalahmah O, Sosunov AA, Shaik A, et al. Single-nucleus RNA-seq identifies Huntington disease astrocyte states. Acta Neuropathol Commun. 2020;8(1). doi: 10.1186/s40478-020-0880-6.
   Web of Science ®Google Scholar
• Diaz-Castro B, Gangwani MR, Yu X, et al. Astrocyte molecular signatures in Huntington’s disease. Sci Transl Med. 2019;11(514):8546. Available from: https://www.science.org/doi/10.1126/scitranslmed.aaw8546
   Web of Science ®Google Scholar
• Estevez-Fraga C, Altmann A, Parker CS, et al. Genetic topography and cortical cell loss in Huntington’s disease link development and neurodegeneration. Brain. 2023;146(11):4532–4546.
   PubMed Web of Science ®Google Scholar
• Smith ES, Jonason A, Reilly C, et al. SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease. Neurobiol Dis. 2015;73:254–268. Available from: https://pubmed.ncbi.nlm.nih.gov/25461192/
   PubMed Web of Science ®Google Scholar
• Basile JR, Gavard J, Gutkind JS Plexin-B1 utilizes RhoA and Rho kinase to promote the integrin-dependent activation of Akt and ERK and endothelial cell motility. J Biol Chem. 2007;282(48):34888–34895. Available from: https://pubmed.ncbi.nlm.nih.gov/17855350/
   PubMed Web of Science ®Google Scholar
• Okuno T, Nakatsuji Y, Moriya M, et al. Roles of Sema4D-plexin-B1 interactions in the central nervous system for pathogenesis of experimental autoimmune encephalomyelitis. J Immunol. 2010;184(3):1499–1506. Available from: https://pubmed.ncbi.nlm.nih.gov/20038643/
   PubMed Web of Science ®Google Scholar
• Southwell AL, Franciosi S, Villanueva EB, et al. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiol Dis. 2015;76:46–56.
   PubMed Web of Science ®Google Scholar
• Feigin A, Evans EE, Fisher TL, et al. Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial. Nat Med. 2022;28(10):2183–2193. Available from: https://www.nature.com/articles/s41591-022-01919-8
   PubMed Web of Science ®Google Scholar
• Lim RG, Quan C, Reyes-Ortiz AM, et al. Huntington’s disease iPSC-derived brain microvascular endothelial cells reveal WNT-mediated angiogenic and blood-brain barrier deficits. Cell Rep. 2017;19(7):1365–1377. Available from: https://pubmed.ncbi.nlm.nih.gov/28514657/
   PubMed Web of Science ®Google Scholar
• Vignone D, Gonzalez Paz O, Fini I, et al. Modelling the human blood-brain barrier in Huntington disease. Int J Mol Sci. 202223;23(14):7813. Available from: https://pubmed.ncbi.nlm.nih.gov/35887162/
   PubMed Web of Science ®Google Scholar
• Drouin-Ouellet J, Sawiak SJ, Cisbani G, et al. Cerebrovascular and blood-brain barrier impairments in Huntington’s disease: potential implications for its pathophysiology. Ann Neurol. 2015;78(2):160–177. Available from: https://pubmed.ncbi.nlm.nih.gov/25866151/
   PubMed Web of Science ®Google Scholar
• Träger U, Andre R, Magnusson-Lind A, et al. Characterisation of immune cell function in fragment and full-length Huntington’s disease mouse models. Neurobiol Dis. 2015;73:388–398. Available from: https://pubmed.ncbi.nlm.nih.gov/25447230/
   PubMed Web of Science ®Google Scholar
• Pido-Lopez J, Andre R, Benjamin AC, et al. In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington’s disease. Sci Rep. 2018 8;8(1). Available from: https://pubmed.ncbi.nlm.nih.gov/30061661/
   PubMedGoogle Scholar
• Dahlenburg H, Cameron D, Yang S, et al. A novel Huntington’s disease mouse model to assess the role of neuroinflammation on disease progression and to develop human cell therapies. Stem Cells Transl Med. 2021;10(7):1033. Available from: /pmc/articles/PMC8235129/
   PubMed Web of Science ®Google Scholar
• Lu Z, Bi J, Sun Y, et al. Polyglutamine protein in tumor cells sensitizes tumor cells to natural killer cell cytolysis. Mol Immunol. 2020;124:153–160.
   PubMed Web of Science ®Google Scholar
• Björkqvist M, Wild EJ, Thiele J, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. J Exp Med. 2008;205(8):1869. Available from: /pmc/articles/ PMC2525598/
   PubMed Web of Science ®Google Scholar
• Träger U, Andre R, Lahiri N, et al. HTT-lowering reverses Huntington’s disease immune dysfunction caused by NFκB pathway dysregulation. Brain. 2014;137(3):819–833. Available from: https://pubmed.ncbi.nlm.nih.gov/24459107/
   PubMedGoogle Scholar
• Weiss A, Träger U, Wild EJ, et al. Mutant huntingtin fragmentation in immune cells tracks Huntington’s disease progression. J Clin Invest. 2012;122(10):3731–3736. Available from: https://pubmed.ncbi.nlm.nih.gov/22996692/
   PubMed Web of Science ®Google Scholar
• Miller JRC, Träger U, Andre R, et al. Mutant Huntingtin does not affect the intrinsic phenotype of human huntington’s disease t lymphocytes. PLoS One. 2015:10. Available from: /pmc/articles/PMC4631523/
   Web of Science ®Google Scholar
• Komori M, Blake A, Greenwood M, et al. Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis. Ann Neurol. 2015;78(1):3. Available from: /pmc/articles/PMC5568079/
   PubMed Web of Science ®Google Scholar
• Niemelä V, Burman J, Blennow K, et al. Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington’s disease. PLoS One. 2018:13. Available from: https://pubmed.ncbi.nlm.nih.gov/29474427/
   Web of Science ®Google Scholar
• von Essen MR, Hellem MNN, Vinther-Jensen T, et al. Early intrathecal T helper 17.1 cell activity in Huntington disease. Ann Neurol. 2020;87(2):246–255. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/ana.25647
   PubMed Web of Science ®Google Scholar
• Silvestroni A, Faull RLM, Strand AD, et al. Distinct neuroinflammatory profile in post-mortem human Huntington’s disease. Neuroreport. 2009;20(12):1098–1103. Available from: https://journals.lww.com/neuroreport/fulltext/2009/08050/distinct_neuroinflammatory_profile_in_post_mortem.12.aspx
   PubMed Web of Science ®Google Scholar
• Kaye J, Piryatinsky V, Birnberg T, et al. Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A. 2016:113:E6145–E6152. Available from: https://www.pnas.org/doi/abs/10.1073/pnas.1607843113
   PubMed Web of Science ®Google Scholar
• Garcia-Miralles M, Hong X, Tan LJ, et al. Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Sci Rep. 2016;6(1):6. Available from: https://pubmed.ncbi.nlm.nih.gov/27528441/
   PubMedGoogle Scholar
• Ellrichmann G, Blusch A, Fatoba O, et al. Laquinimod treatment in the R6/2 mouse model. Sci Rep. 2017;7(1). doi: 10.1038/s41598-017-04990-1.
   PubMedGoogle Scholar
• Reilmann R, Anderson KE, Feigin A, et al. Safety and efficacy of laquinimod for Huntington’s disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Neurol. 2024;23(3):243–255. Available from: http://www.thelancet.com/article/S1474442223004544/fulltext
   PubMed Web of Science ®Google Scholar
• Robbins AO, Ho AK, Barker RA Weight changes in Huntington’s disease. Eur J Neurol. 2006:13. Available from: https://pubmed.ncbi.nlm.nih.gov/16879284/.
   Web of Science ®Google Scholar
• Van der Burg JMM, Winqvist A, Aziz NA, et al. Gastrointestinal dysfunction contributes to weight loss in Huntington’s disease mice. Neurobiol Dis. 2011;44(1):1–8. Available from: https://pubmed.ncbi.nlm.nih.gov/21624468/
   PubMed Web of Science ®Google Scholar
• Han Y, Wang B, Gao H, et al. Vagus nerve and underlying impact on the gut microbiota-brain axis in behavior and neurodegenerative diseases. J Inflamm Res. 2022;15:6213. Available from: /pmc/articles/PMC9656367/
   PubMed Web of Science ®Google Scholar
• Gubert C, Kong G, Costello C, et al. Dietary fibre confers therapeutic effects in a preclinical model of Huntington’s disease. Brain Behav Immun. 2024;116:404–418. Available from: https://pubmed.ncbi.nlm.nih.gov/38142919/
   PubMed Web of Science ®Google Scholar
• Kong G, Cao K-A L, Hannan AJ Alterations in the gut fungal community in a mouse model of Huntington’s disease. Microbiol Spectr. 2022:10. Available from: https://pubmed.ncbi.nlm.nih.gov/35262396/.
   Web of Science ®Google Scholar
• Gubert C, Love CJ, Kodikara S, et al. Gene-environment-gut interactions in Huntington’s disease mice are associated with environmental modulation of the gut microbiome. iScience. 2022;25(1):103687. Available from: /pmc/articles/PMC8760441/
   PubMed Web of Science ®Google Scholar
• Kong G, Cao KAL, Judd LM, et al. Microbiome profiling reveals gut dysbiosis in a transgenic mouse model of Huntington’s disease. Neurobiol Dis. 2020:135. Available from: https://pubmed.ncbi.nlm.nih.gov/30194046/
   Web of Science ®Google Scholar
• Kong G, Ellul S, Narayana VK, et al. An integrated metagenomics and metabolomics approach implicates the microbiota-gut-brain axis in the pathogenesis of Huntington’s disease. Neurobiol Dis. 2021:148. Available from: https://pubmed.ncbi.nlm.nih.gov/33249136/
   Web of Science ®Google Scholar
• Gubert C, Choo JM, Love CJ, et al. Faecal microbiota transplant ameliorates gut dysbiosis and cognitive deficits in Huntington’s disease mice. Brain Commun. 2022:4. Available from: https://pubmed.ncbi.nlm.nih.gov/36035436/
   Google Scholar
• Stan TL, Soylu-Kucharz R, Burleigh S, et al. Increased intestinal permeability and gut dysbiosis in the R6/2 mouse model of Huntington’s disease. Sci Rep. 2020;10(1):1–9. Available from: https://www.nature.com/articles/s41598-020-75229-9
   PubMed Web of Science ®Google Scholar
• Radulescu CI, Garcia-Miralles M, Sidik H, et al. Manipulation of microbiota reveals altered callosal myelination and white matter plasticity in a model of Huntington disease. Neurobiol Dis. 2019;127:65–75. Available from: https://pubmed.ncbi.nlm.nih.gov/30802499/
   PubMed Web of Science ®Google Scholar
• Wasser CI, Mercieca EC, Kong G, et al. Gut dysbiosis in Huntington’s disease: associations among gut microbiota, cognitive performance and clinical outcomes. Brain Commun. 2020 2;2(2). Available from: https://pubmed.ncbi.nlm.nih.gov/33005892/
   PubMedGoogle Scholar
• Wasser CI, Mercieca EC, Kong G, et al. A randomized controlled trial of probiotics targeting gut dysbiosis in Huntington’s disease. J Huntingtons Dis. 2023;12(1):43–55. Available from: https://pubmed.ncbi.nlm.nih.gov/37005888/.
   PubMed Web of Science ®Google Scholar
• Du G, Dong W, Yang Q, et al. Altered gut microbiota related to inflammatory responses in patients with Huntington’s disease. Front Immunol. 2021:11. Available from: https://pubmed.ncbi.nlm.nih.gov/33679692/
   Web of Science ®Google Scholar
• Chang KH, Wu YR, Chen YC, et al. Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model. Brain Behav Immun. 2015;44:121–127. Available from: https://pubmed.ncbi.nlm.nih.gov/25266150/
   PubMed Web of Science ®Google Scholar
• Hsiao HY, Chiu FL, Chen CM, et al. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington’s disease. Hum Mol Genet. 2014;23(16):4328–4344. Available from: https://pubmed.ncbi.nlm.nih.gov/24698979/.
   PubMed Web of Science ®Google Scholar
• Pido-Lopez J, Tanudjojo B, Farag S, et al. Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington’s disease by etanercept treatment. Sci Rep. 2019;9(1). doi: 10.1038/s41598-019-43627-3.
   PubMedGoogle Scholar
• Valadão PAC, da S OB, Joviano-Santos JV, et al. Inflammatory changes in peripheral organs in the BACHD murine model of Huntington’s disease. Life Sci. 2019;232:116653.
   PubMed Web of Science ®Google Scholar
• Corey-Bloom J, Aikin AM, Gutierrez AM, et al. Beneficial effects of glatiramer acetate in Huntington’s disease mouse models: evidence for BDNF-elevating and immunomodulatory mechanisms. Brain Res. 2017;1673:102–110. Available from: https://pubmed.ncbi.nlm.nih.gov/28823953/
   PubMed Web of Science ®Google Scholar
• Bondulich MK, Fan Y, Song Y, et al. Ablation of kynurenine 3-monooxygenase rescues plasma inflammatory cytokine levels in the R6/2 mouse model of Huntington’s disease. Sci Rep. 2021;11(1):1–18. Available from: https://www.nature.com/articles/s41598-021-84858-7.
   PubMed Web of Science ®Google Scholar
• Bouchard J, Truong J, Bouchard K, et al. Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington’s disease. J Neurosci. 2012;32(50):18259–18268. Available from: https://pubmed.ncbi.nlm.nih.gov/23238740/.
   PubMed Web of Science ®Google Scholar
• Wertz MH, Pineda SS, Lee H, et al. Interleukin-6 deficiency exacerbates Huntington’s disease model phenotypes. Mol Neurodegener. 2020;15(1):15. Available from: https://pubmed.ncbi.nlm.nih.gov/32448329/.
   PubMed Web of Science ®Google Scholar
• Chambon J, Komal P, Lewitus GM, et al. Early TNF-dependent regulation of excitatory and inhibitory synapses on striatal direct pathway medium spiny neurons in the YAC128 mouse model of Huntington’s disease. J Neurosci. 2023;43(4):672. Available from: /pmc/articles/PMC9888503/
   PubMed Web of Science ®Google Scholar
• Alto LT, Chen X, Ruhn KA, et al. AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington’s disease. PLoS One. 2014;9(5):e96544. Available from: https://pubmed.ncbi.nlm.nih.gov/24824433/.
   PubMed Web of Science ®Google Scholar
• Du G, Dong W, Yang Q, et al. Altered gut microbiota related to inflammatory responses in patients with Huntington’s disease. Front Immunol. 2021;11:603594.
   PubMed Web of Science ®Google Scholar
• Wild E, Magnusson A, Lahiri Swales N, et al. Abnormal peripheral chemokine profile in Huntington’s disease. PLOS Curr. 2011:3. Available from: /pmc/articles/PMC3082446/
   Google Scholar
• Silajdžić E, Rezeli M, Végvári Á, et al. A critical evaluation of inflammatory markers in Huntington’s disease plasma. J Huntingtons Dis. 2013;2(1):125–134. doi: 10.3233/JHD-130049.
   PubMedGoogle Scholar
• You H, Wu T, Du G, et al. Evaluation of blood glial fibrillary acidic protein as a potential marker in Huntington’s disease. Front Neurol. 2021:12. Available from: /pmc/articles/PMC8639701/
   Web of Science ®Google Scholar
• Eide S, Misztal M, Feng ZP Interleukin-6 as a marker of Huntington’s disease progression: systematic review and meta-analysis. Brain Behav Immun Health. 2023;30:100635.
   PubMedGoogle Scholar
• Rodrigues FB, Byrne LM, McColgan P, et al. Cerebrospinal fluid inflammatory biomarkers reflect clinical severity in Huntington’s disease. PLoS One. 2016:11. Available from: /pmc/articles/PMC5033331/
   Web of Science ®Google Scholar
• Dalrymple A, Wild EJ, Joubert R, et al. Proteomic profiling of plasma in Huntington’s disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res. 2007;6(7):2833–2840. Available from: https://pubs.acs.org/doi/abs/10.1021/pr0700753.
   PubMed Web of Science ®Google Scholar
• Corey-Bloom J, Fischer RS, Kim A, et al. Levels of interleukin-6 in saliva, but not plasma, correlate with clinical metrics in Huntington’s disease patients and healthy control subjects. Int J Mol Sci. 2020;21(17):6363. Available from: https://www.mdpi.com/1422-0067/21/17/6363/htm
   PubMed Web of Science ®Google Scholar
• Sánchez-López F, Tasset I, Agüera E, et al. Oxidative stress and inflammation biomarkers in the blood of patients with Huntington’s disease. Neurol Res. 2012;34(7):721–724. Available from: https://www.tandfonline.com/doi/abs/10.1179/1743132812Y.0000000073.
   PubMed Web of Science ®Google Scholar
• Wang R, Ross CA, Cai H, et al. Metabolic and hormonal signatures in pre-manifest and manifest Huntington’s disease patients. Front Physiol. 2014 5;5. Available from: https://pubmed.ncbi.nlm.nih.gov/25002850/
   Web of Science ®Google Scholar
• Baldacci F, Lista S, Cavedo E, et al. Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer’s disease and other neurodegenerative diseases. Expert Rev Proteomics. 2017;14(4):285–299. Available from: https://pubmed.ncbi.nlm.nih.gov/28281838/
   PubMed Web of Science ®Google Scholar
• Bonneh-Barkay D, Bissel SJ, Kofler J, et al. Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol. 2012;22(4):530–546. Available from: https://pubmed.ncbi.nlm.nih.gov/22074331/
   PubMed Web of Science ®Google Scholar
• Vinther-Jensen T, Börnsen L, Budtz-Jørgensen E, et al. Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease. Neurol Neuroimmunol Neuroinflamm. 2016;3(6). doi: 10.1212/NXI.0000000000000287.
   PubMed Web of Science ®Google Scholar
• Vinther-Jensen T, Budtz-Jørgensen E, Simonsen AH, et al. YKL-40 in cerebrospinal fluid in Huntington’s disease–a role in pathology or a nonspecific response to inflammation? Parkinsonism Relat Disord. 2014;20(11):1301–1303. Available from: https://pubmed.ncbi.nlm.nih.gov/25219973/
   PubMed Web of Science ®Google Scholar
• Dunkelberger JR, Song WC Complement and its role in innate and adaptive immune responses. Cell Res. 2010;20(1):34–50. Available from: https://www.nature.com/articles/cr2009139
   PubMed Web of Science ®Google Scholar
• Larkin PB, Muchowski PJ Genetic deficiency of complement component 3 does not alter disease progression in a mouse model of Huntington’s disease. J Huntingtons Dis. 2012;1(1):107. Available from: /pmc/articles/PMC3478099/
   PubMedGoogle Scholar
• Hodges A, Strand AD, Aragaki AK, et al. Regional and cellular gene expression changes in human Huntington’s disease brain. Hum Mol Genet. 2006;15(6):965–977.
   PubMed Web of Science ®Google Scholar
• Fang Q, Strand A, Law W, et al. Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease. Mol Cell Proteomics. 2009;8(3):451. Available from: /pmc/articles/PMC2649809/.
   PubMed Web of Science ®Google Scholar
• Caron NS, Haqqani AS, Sandhu A, et al. Cerebrospinal fluid biomarkers for assessing Huntington disease onset and severity. Brain Commun. 2022;4. doi: 10.1093/braincomms/fcac309.
   Google Scholar
• Sivadasan A, Bril V Therapies in Autoimmune Peripheral Neuropathies beyond Intravenous Immunoglobulin, Plasma Exchange and Corticosteroids: an Analytical Review. Transfus Med Rev. 2022;36(4):220–229.
   PubMed Web of Science ®Google Scholar
• Zhang W, Chen Y, Pei H C1q and central nervous system disorders. Front Immunol. 2023;14:1145649.
   PubMed Web of Science ®Google Scholar
• Lansita JA, Mease KM, Qiu H, et al. Nonclinical development of ANX005: a humanized anti-c1q antibody for treatment of autoimmune and neurodegenerative diseases. Int J Toxicol. 2017;36(6):449–462. doi: 10.1177/1091581817740873.
   PubMed Web of Science ®Google Scholar
• Beers B, Bredlau A-L, Bhattacharyya A, et al. J08 A phase 2 open label study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous ANX005 in patients with, or at risk of, manifest Huntington’s disease (HD). J Neurol Neurosurg Psychiatry. 2022;93(A96–A97). Available from: https://jnnp.bmj.com/content/93/Suppl_1/A96.3.
   Google Scholar
• Greenland JC, Cutting E, Kadyan S, et al. Azathioprine immunosuppression and disease modification in Parkinson’s disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol. BMJ Open. 2020;10:e040527. Available from: https://pubmed.ncbi.nlm.nih.gov/33234645/
   PubMed Web of Science ®Google Scholar